The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use ...

Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed ...

Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Theriva Biologics reported that it received positive Scientific ...

In a groundbreaking first for nutrition science, researchers have published pilot clinical trial data showing that the 5-day Fasting Mimicking Diet (FMD) was associated with increased activity of the ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...